Ask VialBase
Warning letter · FDA

FDA Issues 30 Warning Letters to Telehealth Companies for Illegal Marketing of Compounded GLP-1s — VialBase News

FDA announced 30 warning letters to telehealth companies for false or misleading claims regarding compounded GLP-1 products offered on their websites.

Last updated · March 3, 2026

FDA Issues 30 Warning Letters to Telehealth Companies for Illegal Marketing of Compounded GLP-1s

Summary

On March 3, 2026, the FDA announced the issuance of 30 warning letters to telehealth companies for false or misleading claims regarding compounded GLP-1 products (Semaglutide, Tirzepatide) offered on their websites. This action continues the sustained enforcement wave that began with the September 2025 55+ warning letters and has expanded across 2026.

Key Details

  • 30 warning letters issued in a single announcement
  • Targets: telehealth platforms marketing compounded GLP-1 medications
  • Core violations flagged: false equivalence claims with FDA-approved Ozempic/Wegovy/Mounjaro, missing required safety disclosures, continued sales after shortage exemptions expired
  • Builds on the precedent set by the September 2025 enforcement action and October 2025 follow-up letters

Affected Parties

  • Telehealth companies — 30 specific firms named in the warning letters (FDA publishes the list on the warning letters database)
  • Compounding pharmacies supplying these telehealth platforms may face secondary pressure
  • Patients currently receiving compounded products from cited sellers should consult prescribers about transitioning to FDA-approved alternatives where clinically appropriate

Implications

  • Continues the signal — now 2+ years into the post-shortage crackdown — that the FDA is willing to issue warning letters at industrial scale against illegal compounded GLP-1 marketing
  • Reinforces that “research use only” framing and direct-to-consumer marketing of compounded GLP-1s remain a compliance risk even after the initial wave
  • Extends beyond the peptide subculture into mainstream telehealth — companies like those running on Hims/Ro-style stacks are on notice
  • For the peptide research community more broadly, the enforcement precedent continues to apply: similar logic could be extended to other unapproved peptides if the FDA chooses to prioritize them

Sources

Source: FDA →